CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 11,112 Shares

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 11,112 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $21.18, for a total value of $235,352.16. Following the completion of the transaction, the chief technology officer owned 167,317 shares in the company, valued at approximately $3,543,774.06. This trade represents a 6.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Raymond Woo also recently made the following trade(s):

• On Monday, December 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $12.28, for a total value of $136,455.36.
• On Tuesday, November 11th, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $12.28, for a total value of $136,455.36.

CeriBell Trading Up 4.4%

Shares of NASDAQ:CBLL opened at $21.73 on Wednesday. The stock’s 50-day simple moving average is $17.33 and its two-hundred day simple moving average is $14.97. The stock has a market capitalization of $806.18 million, a price-to-earnings ratio of -14.39 and a beta of 1.02. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $26.04. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.06. The firm had revenue of $22.59 million for the quarter, compared to analysts’ expectations of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. Analysts expect that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock valued at $16,935,000 after buying an additional 147,013 shares in the last quarter. Yu Fan boosted its position in shares of CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after acquiring an additional 130,964 shares during the last quarter. Novo Holdings A S grew its stake in CeriBell by 2.3% during the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after acquiring an additional 20,000 shares in the last quarter. TimesSquare Capital Management LLC increased its holdings in CeriBell by 2.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock valued at $9,395,000 after acquiring an additional 20,700 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in CeriBell by 41.8% in the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock worth $7,657,000 after purchasing an additional 196,299 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently commented on CBLL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Canaccord Genuity Group raised their price objective on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research note on Monday, December 15th. Finally, Raymond James Financial initiated coverage on shares of CeriBell in a research note on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

More CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: FDA Breakthrough Device designation for CeriBell’s LVO stroke detection/monitoring system — the designation raises the product’s regulatory profile and can accelerate review and access, supporting revenue growth and credibility with hospitals and payors. Ceribell Receives FDA Breakthrough Device Designation
• Neutral Sentiment: Multiple media/analyst outlets are reporting the designation, amplifying investor awareness and likely driving short-term trading interest without adding new technical detail. Zacks: CBLL Wins FDA Breakthrough Status
• Neutral Sentiment: Recent fundamentals: the company beat the last quarter’s revenue and EPS estimates but remains unprofitable with negative margins and analyst forecasts for negative full-year EPS — supportive for growth narrative but underscores ongoing execution and profitability risk.
• Negative Sentiment: Insider sale — CTO Raymond Woo sold 11,112 shares at an average $21.18 on Jan. 2, reducing his stake by ~6.2%; disclosed via SEC filing. Insider selling can be interpreted by some investors as a signal to trim exposure. SEC Filing: Raymond Woo
• Negative Sentiment: Insider sale — Director Rebecca B. Robertson sold 2,500 shares at an average $21.89 on Jan. 2, a roughly 11.3% reduction in her position; disclosed via SEC filing. SEC Filing: Rebecca B. Robertson

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.